Triazineone compounds for treating diseases due to sarcocystis, neospora and toxoplasma
CA 2356181 A1 · Owner: Bayer Corporation · Inventors: Kennedy, Thomas J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed herein is a method of treating therapeutically or metaphylactically , infected animals susceptible to or infected animal suffering from parasitic neurologic or abortigenic diseases such as Sarcocystidiae or Toxoplasmosis that are treatable with triazineone compounds by administering thereto a pharmaceutically effective amount of the compound including a single high , dose therapeutic treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 17, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 17, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 17, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.